08:46 AM EDT, 10/02/2024 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) said Wednesday that the US Food and Drug Administration cleared the company's investigational new drug application for a phase 1/2 trial of REC-1245 as treatment for solid tumors and lymphoma.

The trial, which is scheduled to begin in Q4, will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy of REC-1245, the company said.

Price: 6.20, Change: +0.03, Percent Change: +0.49